<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cayman Journal - Instil Bio Inc (TIL)</title>
    <description>Latest news, press releases, and SEC filings for Instil Bio Inc (TIL)</description>
    <link>https://caymanjournal.com/stock/TIL</link>
    <language>en-us</language>
    
    <copyright>Copyright 2026, Cayman Journal</copyright>
    <managingEditor>editorial@caymanjournal.com (Editorial Team)</managingEditor>
    <webMaster>webmaster@caymanjournal.com (Web Master)</webMaster>
    <lastBuildDate>Tue, 28 Apr 2026 00:06:10 GMT</lastBuildDate>
    <ttl>60</ttl>
    <atom:link href="https://caymanjournal.com/stock/TIL/feed.xml" rel="self" type="application/rss+xml" />
    <image>
      <url>https://caymanjournal.com/logo.png</url>
      <title>Cayman Journal</title>
      <link>https://caymanjournal.com</link>
      <width>144</width>
      <height>144</height>
    </image>

    <item>
      <title>8-K — Instil Bio, Inc.</title>
      <description># 🧾 What This Document Is
This is an **8-K filing**, which is like a company&apos;s &quot;major news bulletin&quot; for the stock market. Instil Bio is using it to report its financial results for the last quarter and full year of 2025, but more importantly, to announce a major strategic shift. They&apos;ve stopped de</description>
      <link>https://caymanjournal.com/stock/TIL/sec-filing/0001789769-26-000018</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/TIL/sec-filing/0001789769-26-000018</guid>
      <pubDate>Fri, 27 Mar 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item>
  </channel>
</rss>